In summary, NaV1.7 isoform is predominantly expressed in prostate cancer and two clinically approved NaV1.7 inhibitors, riluzole and ranolazine, have the potential to be used for the treatment of metastatic PCa. Here, SCN9A is linked to prostate carcinoma.